A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2017
At a glance
- Drugs PD-1 knockout T-cells (Primary) ; Cyclophosphamide; Interleukin-2
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 21 Nov 2016 Status changed from not yet recruiting to recruiting.
- 12 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Jul 2016.